Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island

Overview

Cardiovascular disease (CVD) is the second leading cause of death in France and the leading cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases are well identified and can be easily modulated, in particular by hygiene and dietetic measures (tobacco, sedentary lifestyle). Other risk factors such as high blood pressure, diabetes or dyslipidemia can also be pharmacologically modulated. On the other hand, there is a cardiovascular risk factor that we do not know how to modulate: a high level of lipoprotein (a) (Lp (a)), whose regulation remains largely unknown. High plasma levels of Lipoprotein (a) remain a major risk for the development of cardiovascular disease and its clinical complications, which no drug can currently reduce. Understanding the biological and genetic determinants modulating Lp (a) levels remains a major challenge for treating subjects with hyper Lp (a). Several individuals and possibly Reunion families have been detected as having abnormally high rates of apo (a) Thanks to the link between cardiovascular clinical picture, Lp (a) concentration and other biological markers, the study should allow a better understanding of the mechanisms underlying the cardiovascular risk in order to offer advice. prevention and care of at-risk subjects screened; or even avenues for adapted genetic counseling (DNA sequencing). At the genetic level, several hypotheses could be explored making it possible to link the expression of the apo (a) protein to the genotype, in particular the presence of mutations in the gene, in the promoter region, polymorphisms, or epistatic regulation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2023

Interventions

  • Other: blood lipoprotein (a) test
    • research specific blood sample

Arms, Groups and Cohorts

  • Other: Lipoprotein a level
    • blood lipoprotein (a) test

Clinical Trial Outcome Measures

Primary Measures

  • Carry out a family screening of the plasma Lp (a) level
    • Time Frame: at inclusion
    • Carry out a family screening of the plasma Lp (a) level around index cases followed or directed towards Reunion University Hospital (index case = Lp (a) rate> 200nmol / L)

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with Lp (a)> 200 nmol / L OR member of family of a patient with Lp (a)> 200 nmol / L – be affiliated or beneficiary of a social security scheme – signed consent Exclusion Criteria:

  • Refusal to participate

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de la Réunion
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ilya KHANTALIN, PH, Principal Investigator, CHU de la Réunion
  • Overall Contact(s)
    • Lucie AUZANNEAU, 0262359949, lucie.auzanneau@chu-reunion.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.